Novartis Agrees To Provide Government With Discounted Glivec

Multinational drugmaker Novartis is to provide the Brazilian government with a discount on its oncology therapeutic Glivec (imatinib), indicated for gastrointestinal stromal tumours and for chronic myeloid leukaemia - from BRL42.50 (US$26.61) to BRL20.60 (US$12.90) per 100mg and from BRL170.00 (US$106.45) to BRL82.40 (US$51.60) per 400mg. In 2009, the Brazilian Ministry of Health spent around BRL260mn (US$162mn) on Glivec, accounting for 4.15% of the drug's global sales.

To read the full article, please choose one of the following options: